A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Mean Change in the Symptom Identified by the Patient to be Most Bothersome

Change= Week 12 score - Baseline Score. The most bothersome symptom was derived from the subject self-assessment of vaginal atrophy, which consisted of 5 questions concerning severity of symptoms graded on a scale of 0-3(none, mild, moderate or severe) or 7 for not applicable.

Time frame: Baseline to Week 12

Mean Change in Vaginal pH

Change= Week 12 vaginal pH - Baseline vaginal pH

Time frame: Baseline to Week 12

Mean Change in Maturation Index

Change= Week 12 maturation index -baseline maturation index. Matuation index was calculated using the following equation: Maturation Index = (% Parabasal cells \* 0) + (% Intermediate Cells \* 0.5) + (% Superficial Cells \* 1.0)

Time frame: Baseline to Week 12